243 related articles for article (PubMed ID: 30996218)
21. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
22. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
23. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
25. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Xiao L; Amlashi FG; Elimova E; Blum Murphy MA; Sanders E; Shanbhag N; Thomas I; Ajani JA
Oncology; 2019; 96(5):252-258. PubMed ID: 30893708
[TBL] [Abstract][Full Text] [Related]
26. [A Case of an Elderly Patient with Unresectable Gastric Cancer Treated by Paclitaxel and Ramucirumab].
Kimura Y; Makari Y; Mikami J; Yoshimura J; Inoue T; Sawada G; Nakahira S; Yamamura J; Kamigaki S; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2404-2406. PubMed ID: 28133336
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
[TBL] [Abstract][Full Text] [Related]
28. Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Yoshino S; Furuya T; Shimizu R; Ozasa H; Nishimura T; Fukuda S; Kawaoka T; Hazama S; Oka M
Anticancer Res; 2013 Jun; 33(6):2629-33. PubMed ID: 23749919
[TBL] [Abstract][Full Text] [Related]
29. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
[TBL] [Abstract][Full Text] [Related]
30. [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Nakazawa Y; Kageyama A; Harada D; Kitamura M; Mitsumori N; Kawakubo T
Gan To Kagaku Ryoho; 2019 May; 46(5):901-905. PubMed ID: 31189812
[TBL] [Abstract][Full Text] [Related]
31. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
33. [A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
Seo S; Suzuki T; Misumi T; Tashiro H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1305-1307. PubMed ID: 29394615
[TBL] [Abstract][Full Text] [Related]
34. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
36. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
Muro K; Oh SC; Shimada Y; Lee KW; Yen CJ; Chao Y; Cho JY; Cheng R; Carlesi R; Chandrawansa K; Orlando M; Ohtsu A
J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
[TBL] [Abstract][Full Text] [Related]
37. [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Muroya T; Wajima N; Kubo N; Yoshida E; Akaishi T; Umetsu S; Yoshida T; Wakasa Y; Sato K; Mitsuhashi Y; Umemura K; Ogasawara H; Hara Y; Hakamada K
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2066-2068. PubMed ID: 30692286
[TBL] [Abstract][Full Text] [Related]
38. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R; Izawa N; Suzuki T; Nagahisa Y; Nishikawa K; Takahashi M; Nakamura M; Ishiguro A; Katsuya H; Hihara J; Manaka D; Negoro Y; Tsuji A; Takahashi T; Kochi M; Azuma M; Kadowaki S; Michimae H; Sunakawa Y; Ichikawa W; Fujii M
Target Oncol; 2023 May; 18(3):359-368. PubMed ID: 37060430
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.
Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K
Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419
[TBL] [Abstract][Full Text] [Related]
40. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
